A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. We found that the antidote Andexanet is associated with improved quality-adjusted survival compared with PCC but at a substantial increase in cost. Anticoagulant reversal for life-threatening bleeds.FDA approved in May 2018, limited availability June 2018 with broader commercial launch in early 2019.Inhibits the activity of the Tissue Factor Pathway Inhibitor (TFPI), increasing tissue factor-initiated thrombin generation.Binds and sequesters factor Xa inhibitors.Andexxa to formulary based on a mortality rate should. 2 Download the Product Pricing Brochure to learn more. binant, inactivated-zhzo or formerly andexanet alfa) received accelerated approval from the Food. Dosage Forms: solution reconstituted, 100 mg per vialĪdult Dosing Determined by last dose, type of factor Xa inhibitor, and dose of inhibitorĤ00 mg IV bolus at rate of ~30 mg/minute, followed 2 minutes later by 4 mg/minute for up to 120 minutesĨ00 mg IV bolus at rate of ~30 mg/minute, followed 2 minutes later by 8 mg/minute for up to 120 minutes The wholesale acquisition cost (WAC) for ANDEXXA was reduced by 55 as of April 1, 2022.Type: factor Xa inhibitor reversal, antidote A full HTA is required to assess the clinical effectiveness and cost-effectiveness of andexanet alfa compared with the current standard of care.The median hospital reimbursement was 11,492/hospitalization. 2.1 Determined by last dose, type of factor Xa inhibitor, and dose of inhibitor The median projected cost of andexanet was 22,120/patient, compared to 5670/patient for 4F-PCC (P
0 kommentar(er)
